By contrast, current NCCN and ESMO guidelines recommend FOLFOX or CAPOX for stage III colon cancer (and selected high-risk stage II), total neoadjuvant therapy (TNT) for locally advanced rectal cancer, and routine molecular profiling (RAS, BRAF, MSI-H/dMMR) to guide targeted and immunotherapies in metastatic disease [11,13,14,19,20,21]. This evidence concerns the gene BRAF and rectal cancer.